A dipotassium glycyrrhizinate microemulsion and its preparation method and application

Abstract

The present invention discloses a dipotassium glycyrrhizinate microemulsion and a preparation method and application thereof, and belongs to the technical field of compositions. The dipotassium glycyrrhizinate microemulsion provided by the present invention comprises the following preparation raw materials: dipotassium glycyrrhizinate, water, oil, surfactant, and solvent; the mass percentage of the dipotassium glycyrrhizinate in the preparation raw materials is 2 to 10%. The present invention can form a microemulsion system with small particle size and stable interface by adding dipotassium glycyrrhizinate to the microemulsion and controlling its dosage. The microemulsion can obtain better soothing and anti-inflammatory effects than free dipotassium glycyrrhizinate; and the dipotassium glycyrrhizinate microemulsion of the present invention has good stability in a wide pH range, can adapt to different application scenarios, and has good application prospects in the preparation of stable cosmetics with high anti-inflammatory and soothing activity.

Description

Technical Field

[0001] The invention belongs to the technical field of compositions, and in particular relates to a dipotassium glycyrrhizinate microemulsion and a preparation method and application thereof. Background Art

[0002] Nowadays, with the development of functional skin care products, consumers hope to obtain significant improvement effects in a short period of time after using functional skin care products. However, the existence of the human skin barrier structure makes it difficult for many water-soluble ingredients to quickly enter the skin and take effect. Based on this, many dosage forms have been developed for penetration. Among them, microemulsion technology is introduced into the field of cosmetics from other disciplines, and the surface tension of microemulsion is low, it is easy to moisten the skin, and the structure of the stratum corneum changes, thereby promoting skin absorption. And dipotassium glycyrrhizinate is used as a skin conditioner in the field of cosmetics based on its good anti-allergic, soothing, anti-inflammatory and other effects, and has a long history, but due to its high electrolytic property, it leads to weak percutaneous penetration ability and low bioavailability. The prior art discloses a composition using dipotassium glycyrrhizinate as a stabilizer, but it is necessary to control the pH to 3-4.5, which limits its application in cosmetics. Summary of the invention

[0003] In order to overcome at least one of the problems existing in the above-mentioned prior art, one of the objects of the present invention is to provide a dipotassium glycyrrhizinate microemulsion, which has good stability in a wider pH range and good bioavailability.

[0004] A second object of the present invention is to provide a method for preparing the above-mentioned dipotassium glycyrrhizinate microemulsion.

[0005] A third object of the present invention is to provide a cosmetic.

[0006] In order to achieve the above object, the technical solution adopted by the present invention is:

[0007] The first aspect of the present invention provides a dipotassium glycyrrhizinate microemulsion, comprising the following preparation raw materials: dipotassium glycyrrhizinate, water, oil, surfactant, and solvent; the mass percentage of the dipotassium glycyrrhizinate in the preparation raw materials is 2-10%.

[0008] In some non-limiting specific examples of the present invention, the mass percentage of the dipotassium glycyrrhizinate in the preparation raw material can be selected from 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%, etc.; further preferably, it can be 3-9%.

[0009] In some embodiments of the present invention, the surfactant includes at least one of PPG-13-decyltetradecyl alcohol polyether-24, PEG-60 hydrogenated castor oil, polyglyceryl-3 diisostearate or sorbitan sesquioleate; in some specific embodiments of the present invention, the surfactant includes at least two of PPG-13-decyltetradecyl alcohol polyether-24, PEG-60 hydrogenated castor oil, polyglyceryl-3 diisostearate or sorbitan sesquioleate.

[0010] In the present invention, the addition of a surfactant can make the system have a good emulsification effect. If no surfactant is added, the emulsification of the system will fail and the emulsion will break.

[0011] In some embodiments of the present invention, the solvent includes at least one of glycerol, 1,3-butanediol, 1,3-propylene glycol or dipropylene glycol; in some specific embodiments of the present invention, the solvent includes at least two of glycerol, 1,3-butanediol, 1,3-propylene glycol or dipropylene glycol; in some more specific embodiments of the present invention, the solvent includes glycerol and a combination of at least one of 1,3-butanediol, 1,3-propylene glycol or dipropylene glycol.

[0012] In some embodiments of the present invention, the oil is a liquid oil. The liquid oil of the present invention is a commonly used liquid oil in cosmetics, which is not limited here. In some specific embodiments of the present invention, the oil includes at least one of tocopherol acetate, squalane, tocopherol (also known as vitamin E) or diisostearyl malate; in some more specific embodiments of the present invention, the oil includes tocopherol acetate, squalane, tocopherol (also known as vitamin E) and diisostearyl malate.

[0013] In some embodiments of the present invention, the interface of the microemulsion contains dipotassium glycyrrhizinate. In some specific embodiments of the present invention, the dipotassium glycyrrhizinate participates in the assembly of the microemulsion interface, so that the interface of the microemulsion contains dipotassium glycyrrhizinate.

[0014] The interface of the microemulsion described in the present invention refers to the water-oil interface of the microemulsion; that is, dipotassium glycyrrhizinate is at the water-oil interface of the microemulsion, so that the microemulsion has good interface stability and anti-inflammatory and soothing effects. Specifically, the mixing order of the raw materials can be adjusted so that dipotassium glycyrrhizinate participates in the assembly of the microemulsion interface, thereby making the interface of the microemulsion contain dipotassium glycyrrhizinate.

[0015] In some embodiments of the present invention, the dipotassium oxalate microemulsion comprises the following raw materials in parts by weight: 2 to 10 parts of dipotassium glycyrrhizinate, 1 to 12 parts of water, 5 to 30 parts of oil, 10 to 25 parts of surfactant, and 20 to 80 parts of solvent; in some specific embodiments of the present invention, the dipotassium oxalate microemulsion comprises the following raw materials in parts by weight: 2 to 10 parts of dipotassium glycyrrhizinate, 2 to 10 parts of water, 10 to 25 parts of oil, 12 to 20 parts of surfactant, and 40 to 70 parts of solvent.

[0016] In some embodiments of the present invention, the average particle size of the dipotassium glycyrrhizinate microemulsion is ≤100 nm; in some specific embodiments of the present invention, the average particle size of the dipotassium glycyrrhizinate microemulsion is 20-100 nm; in some more specific embodiments of the present invention, the average particle size of the dipotassium glycyrrhizinate microemulsion is 40-80 nm; non-limiting specific examples are 40 nm, 50 nm, 60 nm, 70 nm or 80 nm.

[0017] In some embodiments of the present invention, the pH value of the dipotassium glycyrrhizinate microemulsion is 3-7; in some specific embodiments of the present invention, the pH value of the dipotassium glycyrrhizinate microemulsion is 5-7; non-limiting specific examples are 5, 5.5, 6, 6.5 or 7.

[0018] The dipotassium glycyrrhizinate microemulsion of the present invention can remain stable within a wide pH range (such as a pH of 3 to 7), which effectively broadens the application scenarios of the microemulsion and enables it to adapt to the use requirements of different products.

[0019] In some embodiments of the present invention, the raw materials for preparing the dipotassium glycyrrhizinate microemulsion further include an oil-soluble active ingredient.

[0020] Adding oil-soluble active ingredients to the raw materials for preparing microemulsions can make them miscible with oils and fats to form dipotassium glycyrrhizinate microemulsions containing active ingredients, thereby further enriching the functions of the microemulsions or improving the anti-inflammatory and soothing effects of the microemulsions.

[0021] In other embodiments of the present invention, the raw materials for preparing the dipotassium glycyrrhizinate microemulsion do not include oil-soluble active ingredients.

[0022] Without adding other active ingredients, the dipotassium glycyrrhizinate microemulsion of the present invention can achieve good anti-inflammatory and soothing effects, and has a simple preparation process and low cost.

[0023] The second aspect of the present invention provides a method for preparing the dipotassium glycyrrhizinate microemulsion according to the first aspect of the present invention, comprising the following steps: mixing dipotassium glycyrrhizinate, a surfactant and a solvent, then adding oil and mixing, and finally adding water and mixing to obtain the dipotassium glycyrrhizinate microemulsion.

[0024] The present invention adopts a specific mixing sequence, so that dipotassium glycyrrhizinate can be placed on the microemulsion interface, thereby obtaining good interface stability, effectively exerting the biological activity of dipotassium glycyrrhizinate, and giving the dipotassium glycyrrhizinate microemulsion good soothing and anti-inflammatory effects.

[0025] In some embodiments of the present invention, the temperature for mixing dipotassium glycyrrhizinate, the surfactant and the solvent is 70-90°C; non-limiting specific examples are 70°C, 75°C, 80°C, 85°C or 90°C.

[0026] In some embodiments of the present invention, the temperature for adding the oil and fat for mixing is 70-90°C; non-limiting specific examples are 70°C, 75°C, 80°C, 85°C or 90°C.

[0027] In some embodiments of the present invention, the temperature for mixing dipotassium glycyrrhizinate, the surfactant and the solvent is the same as the temperature for adding the oil and mixing.

[0028] In some embodiments of the present invention, the temperature for adding water for mixing is 40-60°C; non-limiting specific examples are 40°C, 45°C, 50°C, 5°C or 60°C.

[0029] The third aspect of the present invention provides a cosmetic, wherein the raw materials for preparing the cosmetic include the dipotassium glycyrrhizinate microemulsion described in the first aspect of the present invention.

[0030] In some embodiments of the present invention, the mass percentage of the dipotassium glycyrrhizinate microemulsion in the raw materials for preparing the cosmetic is 0.1-10%; in some specific embodiments of the present invention, the mass percentage of the dipotassium glycyrrhizinate microemulsion in the raw materials for preparing the cosmetic is 0.5-5%; non-limiting specific examples are 0.5%, 1%, 2%, 3%, 4% or 5%.

[0031] In some embodiments of the present invention, the pH value of the cosmetic is 3-7; in some specific embodiments of the present invention, the pH value of the cosmetic is 5-7; non-limiting specific examples are 5, 5.5, 6, 6.5 or 7.

[0032] The dipotassium glycyrrhizinate microemulsion provided by the invention can remain stable in a wider pH value range, so the cosmetics prepared by using the dipotassium glycyrrhizinate microemulsion can also obtain a wider pH value range, for example, the cosmetics can remain stable in the pH value range of 3 to 7.

[0033] The beneficial effects of the present invention are as follows: the present invention can form a microemulsion system with small particle size and stable interface by adding dipotassium glycyrrhizinate into the microemulsion and controlling the dosage thereof; the microemulsion can obtain better soothing and anti-inflammatory effects than free dipotassium glycyrrhizinate; and the dipotassium glycyrrhizinate microemulsion of the present invention has good stability in a wide pH range, can adapt to different application scenarios, and has good application prospects in the preparation of stable cosmetics with high anti-inflammatory and soothing activities. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 The cell survival rate data of Comparative Examples 4 to 5 and Example 8 of the present invention are shown.

[0035] Figure 2 The data are NO inhibition rates of Comparative Examples 4 to 5 and Example 8 of the present invention.

[0036] Figure 3 These are the stability test results of the sample of Example 8 of the present invention at pH values ​​of 3.0 and pH values ​​of 7.0. DETAILED DESCRIPTION

[0037] The content of the present invention is further described in detail below through specific examples. It should also be understood that the following examples are only used to further illustrate the present invention and cannot be construed as limiting the scope of protection of the present invention. Some non-essential improvements and adjustments made by those skilled in the art based on the principles set forth in the present invention all belong to the scope of protection of the present invention. The specific process parameters and the like in the following examples are also only examples within a suitable range, that is, those skilled in the art can make a selection within a suitable range through the description herein, and are not limited to the specific data exemplified below. The raw materials, reagents or devices used in the following examples and comparative examples, unless otherwise specified, can all be obtained from conventional commercial sources, or can be obtained by existing known methods.

[0038] Example 1

[0039] This example provides a dipotassium glycyrrhizinate microemulsion, the raw materials for its preparation are shown in Table 1, and the specific preparation method is as follows:

[0040] S1. Weigh and mix the raw materials of phase A respectively, heat the system to 70-90°C, stir until completely dissolved, and keep warm;

[0041] S2. Slowly add phase B and stir until completely dissolved;

[0042] S3, slowly add phase C, keep warm and stir for 10 minutes;

[0043] S4. Cool down to 40-60℃, add water, stir evenly, and cool to room temperature.

[0044] Embodiments 2 to 5

[0045] Examples 2 to 5 each provide a dipotassium glycyrrhizinate microemulsion, which differs from Example 1 in that the raw materials and dosages are different. The raw materials and dosages of Examples 2 to 5 are shown in Table 1; the specific preparation method is the same as that of Example 1.

[0046] Particle size testing

[0047] The microemulsions obtained in Examples 1 to 5 were tested for particle size, and the specific steps were as follows: 0.1 g of sample was taken, water was added to 40 g, and the mixture was stirred evenly, and the particle size was analyzed in a particle size analyzer (instrument model: Zetasizer Lab).

[0048] The particle size test results of Examples 1 to 5 are shown in Table 1. It can be seen that the particle sizes of Examples 1 to 5 are all less than 100 nm, and the particle sizes are good.

[0049] Table 1 Raw materials and their dosage and particle size test results of Examples 1 to 5 (dosage units are wt%)

[0050]

[0051]

[0052] Examples 6 to 8 and Comparative Examples 1 to 3

[0053] Examples 6 to 8 and Comparative Examples 1 to 3 each provide a dipotassium glycyrrhizinate microemulsion, which differs from Example 1 in that the raw materials and dosages are different. The raw materials and dosages of Examples 6 to 8 and Comparative Examples 1 to 3 are shown in Table 2; the specific preparation method is the same as that of Example 1.

[0054] Particle size testing

[0055] The microemulsions obtained in Examples 6 to 8 and Comparative Examples 1 to 3 were tested for particle size, and the specific steps were as follows: 0.1 g of sample was taken, water was added to 40 g, and the mixture was stirred evenly, and the particle size was analyzed in a particle size analyzer (instrument model: Zetasizer Lab).

[0056] The particle size test results of Examples 6 to 8 and Comparative Examples 1 to 3 are shown in Table 2. It can be seen that the change in the amount of dipotassium glycyrrhizinate will affect the particle size of the microemulsion system. Dipotassium glycyrrhizinate has a certain concentration range requirement in the microemulsion system. When its concentration is lower than 2% and higher than 10%, the obtained microemulsion particle size effect will deteriorate, and a particle size within 100 nm cannot be formed.

[0057] Table 2 Raw materials and their dosage and particle size test results of Examples 6 to 8 and Comparative Examples 1 to 3 (dosage units are wt%)

[0058]

[0059]

[0060] Comparative Example 4

[0061] This example provides a dipotassium glycyrrhizinate microemulsion, which is different from Example 8 in that this example does not include dipotassium glycyrrhizinate, and the reduced dipotassium glycyrrhizinate is replaced by an equal amount of water; the specific preparation method is the same as that of Example 8.

[0062] Comparative Example 5

[0063] This example provides a dipotassium glycyrrhizinate microemulsion. The raw materials and dosage are the same as those in Example 8. The difference from Example 8 is that the preparation method is different. In this example, dipotassium glycyrrhizinate is added after the emulsion is formed, so that the dipotassium glycyrrhizinate is not on the interface of the microemulsion but in a free state. The specific preparation method is as follows:

[0064] S1. Weigh each component of phase A separately, heat the system to 70-90°C, stir until completely dissolved, and keep warm;

[0065] S2, slowly add phase C, keep warm and stir for 10 minutes;

[0066] S3, cool down to 40-60℃, add water, stir evenly, and cool to room temperature;

[0067] S4. Add phase B and stir until completely dissolved.

[0068] The raw materials and their amounts of Comparative Examples 4-5 and Example 8 are shown in Table 3.

[0069] Table 3 Raw materials and their dosages of Comparative Examples 4 to 5 and Example 8 (dosage units are wt%)

[0070]

[0071]

[0072] Performance Testing

[0073] 11.36 g of the microemulsions of Comparative Examples 4-5 and Example 8 were taken respectively, diluted to 100 g with water, and samples 1-3 were obtained for the following tests. Among them, the concentration of dipotassium glycyrrhizinate in the microemulsions of Comparative Example 5 and Example 8 was 8.8%, and the concentration of dipotassium glycyrrhizinate in samples 2-3 obtained after dilution was 1%; and the concentration of dipotassium glycyrrhizinate in sample 1 was 0%.

[0074] Soothing effect means that it helps to improve conditions such as skin irritation. Different types of experimental methods can be used to verify it. The present invention refers to the method of group standard T / SHRH 034-2021, and uses the Raw264.7 cell inflammatory factor detection test to test the efficacy of the sample. Lipopolysaccharide (LPS) is the main component of the cell wall of Gram-negative bacteria. It can cause inflammatory reactions in mammalian cells and release a large amount of inflammatory mediators, such as nitric oxide (NO). Excessive NO will further produce reactive nitrogen free radicals, attack biological macromolecules such as DNA and protein, and cause cell and tissue damage. Different concentrations of the test substance act on Raw264.7 cells after LPS modeling, and the level of NO cell inflammatory factors is detected to determine whether the test substance has a soothing effect.

[0075] (1) CCK8 detection of cytotoxicity:

[0076] The pre-cultured Raw264.7 cells were centrifuged and the supernatant was removed. The cells were resuspended in culture medium at a concentration of 1×10 5 100 μL of culture medium were added to the blank control and 200 μL of gradient concentration samples were added to the sample group; 24 hours after adding the sample, DMEM containing CCK-8 was added, and after culture, the sample was detected at 450 nm to find out the concentration at which the cell survival rate of the sample was greater than 90%.

[0077] All test data were first deducted from the background control, and the survival rate of the blank control group was 100%. The effect of the sample on Raw264.7 cells was calculated using the following formula:

[0078] Cell viability (%) = OD450 样品组 / OD450 空白对照组 ×100%.

[0079] (2) Detection of inflammatory factors

[0080] The pre-cultured Raw264.7 cells were centrifuged and the supernatant was removed. The cells were resuspended in culture medium at a concentration of 1×10 5 / well, inoculated into 96-well plates for exposure; 24 hours after plating, discard the old culture medium, add 200 μL culture medium to the blank control, add 200 μL LPS solution (concentration of 1 μg / mL) to the LPS model group, and add 100 μL LPS solution (concentration of 2 μg / mL) and 100 μL sample to the sample group; 24 hours after adding the sample, aspirate the upper culture medium, and use the NO kit to detect the level of inflammatory factors.

[0081] The premise of inflammatory factor detection is that the cell survival rate is above 90%. The NO detection data is first deducted from the background control, the generation rate of the LPS model group is 100%, and the inhibition rate is 0%. The effect of the sample on the NO generation rate or inhibition rate is calculated. The calculation formula is as follows:

[0082] NO generation rate (%) = OD540 样品组 / OD540 LPS模型组 ×100%;

[0083] NO inhibition rate (%) = 100% - (OD540 样品组 / OD540 LPS模型组 ×100%).

[0084] The one-way ANOVE method was used to calculate the significant difference between the sample group and the LPS model group. * represents P < 0.05, indicating a significant difference.

[0085] The experimental results are as follows Figure 1 and Figure 2 shown. Figure 1 The cell survival rate data of Comparative Examples 4 to 5 and Example 8, Figure 2 The NO inhibition rate data of Comparative Examples 4 to 5 and Example 8, wherein Sample 1 is obtained from the microemulsion of Comparative Example 4, Sample 2 is obtained from the microemulsion of Comparative Example 5, and Sample 3 is obtained from the microemulsion of Example 8. Figures 1-2 It can be seen that the dipotassium glycyrrhizinate microemulsion interface of Example 8 of the present invention has a significant improvement in NO inhibition rate compared with the non-dipotassium glycyrrhizinate interface microemulsion in Comparative Examples 4 to 5, indicating that the soothing effect of the dipotassium glycyrrhizinate microemulsion of the present invention is significantly enhanced.

[0086] (3) Stability of microemulsions at different pH values

[0087] The samples at different pH values ​​were analyzed using a LUMiSizer stability analyzer. The sample was a 2% aqueous solution of Example 8, and the pH values ​​were adjusted to 3.0 and 7.0 using 10% citric acid and 0.5% NaOH aqueous solutions, respectively.

[0088] Experimental instrument: LUMiSizer 6113-137 (12 channels).

[0089] The experimental conditions are shown in the following table:

[0090] Table 4 Experimental conditions for pH stability test of microemulsion

[0091] Contour Time interval Duration Speed Light Factor temperature 1000 20s 19,999s 4000r / min 1.00 45.0℃

[0092] The experimental results are as follows Figure 3 As shown, Figure 3The stability test results of the sample of Example 8 at pH 3.0 and pH 7.0, wherein (a) is pH 3.0 and (b) is pH 7.0. Figure 3 It can be seen that under the experimental conditions of Table 4, the transmittance of the sample was tested every 20 seconds, and a total of 19,999 seconds were tested to obtain different transmittance curves, while the transmittance of the two samples with pH values ​​of 3.0 and pH values ​​of 7.0 did not change significantly, indicating that the dipotassium glycyrrhizinate microemulsion of the present invention has good stability when the pH value is 3-7.

[0093] Application Example 1

[0094] This example provides a lotion, the raw materials and amounts are shown in Table 4, and the specific preparation method is as follows:

[0095] Pre-made A1: Take a clean container of appropriate size, weigh the ingredients of pre-made A1, stir evenly, and set aside;

[0096] Pre-made B1: Take a clean container of appropriate size, weigh all ingredients of pre-made B1, stir until completely dissolved, and set aside;

[0097] S1. Take a clean container, weigh phase A, heat to 80℃ with stirring until completely dissolved;

[0098] S2. Add the preformed A1 at 80°C, stir until completely dissolved, and cool to 45°C;

[0099] S3. At 45°C, add the pre-made B1 and B phase ingredients respectively, stir evenly, and cool to 38°C or below.

[0100] Table 4 Raw materials and dosage of Application Example 1 (dosage unit is wt%)

[0101]

[0102]

[0103] Performance Testing

[0104] The stability and pH value of the lotion prepared in Application Example 1 under different storage conditions were tested, and the results are shown in Table 5. The appearance, shape and smell of the samples under different storage conditions are the results compared with the samples on day 0. As can be seen from Table 5, the lotion obtained in Application Example 1 of the present invention has good stability, the pH value is maintained at about 6, and the blue transparent property of the microemulsion is always maintained, indicating that the dipotassium glycyrrhizinate microemulsion prepared in the embodiment of the present invention can maintain the stability of the interface for a long time.

[0105] Table 5 Stability test data of application example 1

[0106] Test indicators Day 0 45℃ 3 months 5℃ 3 months Freeze and thaw 5 times 3 months of light pH 6.21 6.03 6.18 6.11 6.02 Appearance Blue transparent No significant changes No significant changes No significant changes No significant changes odor Characteristic smell No significant changes No significant changes No significant changes No significant changes

[0107] From the above embodiments, application examples and comparative examples, it can be seen that the present invention combines a certain concentration of dipotassium glycyrrhizinate with raw materials such as a surfactant through the dosage and process limitation of dipotassium glycyrrhizinate to form a microemulsion interface with a particle size of less than 100 nm, thereby obtaining a good soothing and anti-inflammatory effect; and it has good stability in a wider pH range.

[0108] In summary, the present invention can form a microemulsion system with small particle size and stable interface by adding dipotassium glycyrrhizinate into the microemulsion and controlling the amount thereof. Compared with free dipotassium glycyrrhizinate, the microemulsion can obtain better soothing and anti-inflammatory effects; and the dipotassium glycyrrhizinate microemulsion of the present invention has good stability in a wide pH range, can adapt to different application scenarios, and has good application prospects in the preparation of stable cosmetics with high anti-inflammatory and soothing activity.

Claims

1. A dipotassium glycyrrhizinate microemulsion, characterized in that: The preparation method comprises the following raw materials: dipotassium glycyrrhizinate, water, oil, surfactant and solvent; the mass percentage of the dipotassium glycyrrhizinate in the raw materials is 2-10%.

2. The dipotassium glycyrrhizinate microemulsion according to claim 1, characterized in that: The surfactant includes at least one of PPG-13-decyltetradecyl alcohol polyether-24, PEG-60 hydrogenated castor oil, polyglyceryl-3 diisostearate or sorbitan sesquioleate.

3. The dipotassium glycyrrhizinate microemulsion according to claim 1, characterized in that: The solvent includes at least one of glycerol, 1,3-butylene glycol, 1,3-propylene glycol or dipropylene glycol.

4. The dipotassium glycyrrhizinate microemulsion according to claim 1, characterized in that: The interface of the microemulsion contains dipotassium glycyrrhizinate.

5. The dipotassium glycyrrhizinate microemulsion according to claim 1, characterized in that: The dipotassium oxalate microemulsion comprises the following raw materials in parts by weight: 2 to 10 parts of dipotassium glycyrrhizinate, 1 to 12 parts of water, 5 to 30 parts of oil, 10 to 25 parts of surfactant, and 20 to 80 parts of solvent.

6. The dipotassium glycyrrhizinate microemulsion according to any one of claims 1 to 5, characterized in that: The average particle size of the dipotassium glycyrrhizinate microemulsion is ≤100 nm; And / or, the pH value of the dipotassium glycyrrhizinate microemulsion is 3-7.

7. A method for preparing the dipotassium glycyrrhizinate microemulsion according to any one of claims 1 to 6, characterized in that: The method comprises the following steps: mixing dipotassium glycyrrhizinate, a surfactant and a solvent, then adding oil and mixing, and finally adding water and mixing to obtain the dipotassium glycyrrhizinate microemulsion.

8. The preparation method according to claim 7, characterized in that: The temperature of mixing dipotassium glycyrrhizinate, surfactant and solvent is 70-90°C; and / or, the temperature at which the oil is added and mixed is 70 to 90°C; And / or, the temperature for adding water and mixing is 40 to 60°C.

9. A cosmetic, characterized in that: The raw materials for preparing the cosmetics include the dipotassium glycyrrhizinate microemulsion according to any one of claims 1 to 6.

10. The cosmetic according to claim 9, characterized in that: The mass percentage of the dipotassium glycyrrhizinate microemulsion in the raw materials for preparing the cosmetic is 0.1 to 10%; And / or, the pH value of the cosmetic is 3-7.

Images